NDAORALTABLET
Approved
May 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROPRES 25 is a fixed-dose combination oral tablet containing hydrochlorothiazide (a thiazide diuretic) and reserpine (an antihypertensive alkaloid) approved in 1974 for the treatment of hypertension. The combination works through dual mechanisms: hydrochlorothiazide reduces blood volume and sodium reabsorption, while reserpine depletes catecholamine stores in sympathetic neurons. This product represents a legacy antihypertensive therapy from the pre-modern era of hypertension management.
LOE Approaching
This legacy product is in late-stage lifecycle with minimal commercial investment; roles are primarily defensive/maintenance-focused rather than growth-oriented.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYDROPRES 25 offers limited career growth potential given its LOE-approaching lifecycle and zero linked job openings; this role would be suitable only for professionals seeking stability in a maintenance-focused position or gaining experience in legacy product management. Career mobility is constrained by the product's declining relevance and minimal commercial investment.
Product Manager (Legacy/Maintenance)
Worked on HYDROPRES 25 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.